Cart
sales@molnova.com
Chk
CSK-homologous kinase (CHK), a protein kinase that displays significant sequence similarity with CSK. Depending on its structural features and the origins of the cDNA libraries, CHK was also named Hyl, BatK, Matk, Ctk and Ntk. Both CSK and CHK are cytosolic protein tyrosine kinases. Membrane translocation of CHK is mainly mediated by binding to membrane proteins and signaling adaptor proteins via their SH2, SH3 and/or kinase domains CHK is recruited to the plasma membrane by binding to membrane proteins ErbB2, c-Kit, and TrkA via its SH2 domain. Deletion of the SH3 domain abolishes the abilities of CHK to anchor to the plasma membrane to inhibit Lyn, and to suppress cell spreading. Mutation of Ser-78 in the SH3 –SH2 connector of CHK resulted in a significant loss of activity. CHK may perform unique functions in the nucleus and these functions are related to the ability of CHK to suppress myeloid cell growth.
References
1.Chong YP,et al. Growth Factors. 2005 Sep;23(3):233-44.
References
1.Chong YP,et al. Growth Factors. 2005 Sep;23(3):233-44.
Angiogenesis
Chk
-
4-Demethyldeoxypodophyllotoxin
catalog no : M37321
cas no: 3590-93-0
4-Demethyldeoxypodophyllotoxin, an aryl tetrahydronaphthalenyl lignan analog from the roots of Podophyllum peltatum, has anticancer activity and modulates the Chk-2 signaling pathway in MCF-7 breast cancer cells.
-
PHI-101
catalog no : M37298
cas no: 2127107-15-5
PHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer.
-
Monalizumab
catalog no : M36667
cas no: 1228763-95-8
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).
-
Tuvusertib
catalog no : M32792
cas no: 1613200-51-3
Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 μΜ) with selective and potentially antitumor activity.
-
GDC0575 monohydrochloride
catalog no : M27878
cas no: 1196504-54-7
GDC-0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis.